Latest News and Press Releases

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On...

WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...

HONG KONG, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inno Holdings Inc. (NASDAQ: INHD) (the “Company”), a trade-focused building technology and electronic products trading company, today announced that it...

Imagine stepping into a suite that smells like cookies, sparkles with holiday lights and feels more like a storybook kitchen than a high-rise hotel.

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program...

Strong Q3 results: Q3’25 represents another quarter of Rule-of-30, with revenue above the midpoint and Adjusted EBITDA exceeding the high end of our guidance. The continued growth of AI, upmarket, and...

Existing Steakholder Shareholders Retain Majority Stake; Twine Shareholders Previously Invested in Steakholder and Provided Convertible Loan Since Converted into Equity, Both at a Substantial Premium ...

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...

New York, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Identifying ways that we can optimize Borderline Personality Disorder (BPD) treatment and prevention is an important public health priority. One area for...

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...